IL18 and acute kidney injury: Despite the progress in identifying novel biomarkers of AKI, such as kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin-2 (NGAL), and interleukin-18 (IL-18), their use in clinical practice is limited due to lack of cut off values as well as validation studies in larger population2,3.